Posted by Michael Wonder on 03 May 2018
Migraine drug delay would compound Teva's troubles
2 May 2018 - Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.
U.S. regulatory concerns about the manufacturing process could push approval of fremanezumab back to 2019. This is likely to put the Israeli drugmaker behind two of its rivals - Amgen and Eli Lilly - in the race to market for a migraine treatment, according to industry experts.
“Teva will have to align with the pricing dynamics of the prior two launches rather than lead the pricing policy with payers,” Meitav Dash Investments analyst Jonathan Kreizman said. “They won’t be able to impose any meaningful price differences from what already will be in the market.”
